logo-loader

Biocept is changing the way physicians examine blood work for their cancer patients and doing coronavirus testing

Last updated: 08:35 14 Aug 2023 EDT, First published: 06:15 05 Oct 2021 EDT

Snapshot

  • Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference
cancer cell

About the company

Biocept, Inc. is a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. The company's patented Target Selector liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both CTCs and in plasma (ctDNA). Biocept offers single biomarker tests for lung, breast, melanoma, gastric, colorectal, and prostate cancers that can be used for treatment selection and response monitoring. The company also offers tumor-specific multi-gene next-generation sequencing (NGS) panels for both lung and breast cancer.  With thousands of tests performed, Biocept’s liquid biopsy platforms have demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options.

How it is doing

14 Aug 2023

Biocept Inc (NASDAQ:BIOC) said that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 Society for Neuro-Oncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Cancer Conference which was held in San Fransico between August 10 and 12.

The two abstracts presented were titled 'The HER2 Flip: HER2 Amplification of Tumor Cells in the Cerebrospinal Fluid (CSF-TCs) of Patients with Leptomeningeal Metastasis having solid tumors; implications for treating the LM tumor with anti-HER2 therapy', and 'Circulating tumor cell analysis from the cerebrospinal fluid informs early diagnosis, treatment and prognosis in leptomeningeal carcinomatosis (LMC)'.

The abstracts were presented by United Counsel for Neurologic Subspecialties-certified neuro-oncologist at Northwestern University, Dr. Priya U. Kumthekar and director of Neuro-Oncology at the University of California, San Diego Dr. David Piccioni.  

Dr. Kumthekar is the principal investigator of Biocept’s ongoing FORESEE clinical trial, which is evaluating the performance of CNSide for leptomeningeal metastasis (LM) and assessing the impact of CNSide on treatment decisions made by physicians, the company noted.

21 Jun 2023

Biocept Inc (NASDAQ:BIOC) has announced the appointment of Antonino Morales as its president and chief executive officer, effective immediately.

Morales, who has been serving as the company's interim chief financial officer since February 2022 and as a director of the company since July 2021, will now take on the leadership role.

05 Jun 2023

Biocept Inc (NASDAQ:BIOC) said that a poster presentation at the annual American Society of Clinical Oncology (ASCO) demonstrates the impressive ability of the company’s cerebrospinal fluid assay CNSide to detect rates of leptomeningeal metastases, compared with standard CSF cytology from lumbar puncture.

In a nutshell, leptomeningeal metastases (LM), is a type of cancer in the cerebrospinal fluid and membranes that surround a person’s brain and spinal cord (the leptomeninges).

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

4 hours, 5 minutes ago